Published in J Low Genit Tract Dis on January 01, 2005
Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis (2010) 2.03
Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol (2013) 1.02
Single visit approach for management of cervical intraepithelial neoplasia by visual inspection & loop electrosurgical excision procedure. Indian J Med Res (2012) 0.93
See-and-Treat Loop Electrosurgical Excision Procedure for High-Grade Cervical Cytology: Are We Overtreating? J Low Genit Tract Dis (2016) 0.80
Three-step approach versus see-and-treat approach in patients with cytological abnormalities. Int J Clin Exp Med (2013) 0.79
'See-and-treat' works for cervical cancer prevention: what about controlling the high burden in India? Indian J Med Res (2012) 0.78
See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology? J Low Genit Tract Dis (2016) 0.75
Study of 2 years follow-up of referral patients with abnormal Pap smear. J Res Med Sci (2015) 0.75
Loop Electrosurgical Excisional Procedure (LEEP) Done for Discrepancy: Does the Time from HGSIL Affect Pathologic Grade of CIN in LEEP Specimen? Obstet Gynecol Int (2010) 0.75
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol (2011) 2.27
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol (2013) 2.01
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer (2009) 1.98
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol (2006) 1.77
Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol (2013) 1.66
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. Gynecol Oncol (2012) 1.58
The utilization of palliative care in gynecologic oncology patients near the end of life. Gynecol Oncol (2012) 1.56
Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol (2008) 1.54
A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. Obstet Gynecol (2007) 1.49
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol (2005) 1.45
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Knowledge, beliefs, and practices concerning seat belt use during pregnancy. J Trauma (2004) 1.41
Trends in hospital volume and patterns of referral for women with gynecologic cancers: adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol (2013) 1.41
Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol (2002) 1.41
Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol (2003) 1.40
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist (2006) 1.40
Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol Oncol (2002) 1.38
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol (2009) 1.29
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cervical cancer. J Natl Compr Canc Netw (2013) 1.24
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol (2007) 1.23
Comprehensive surgical staging for endometrial cancer in obese patients: comparing robotics and laparotomy. Obstet Gynecol (2009) 1.22
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. Int J Gynecol Cancer (2010) 1.20
Postmenopausal uterine inversion associated with endometrial polyps. Obstet Gynecol (2003) 1.19
Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol (2004) 1.17
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol (2009) 1.14
Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther (2012) 1.13
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Gene therapy for ovarian cancer. Curr Oncol Rep (2006) 1.08
Cervical cancer. J Natl Compr Canc Netw (2010) 1.07
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol (2009) 1.04
A case report of rhabdomyosarcoma of the uterus associated with uterine inversion. Gynecol Oncol (2005) 1.04
A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3. Am J Obstet Gynecol (2003) 1.04
Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 1.04
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother (2008) 1.04
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res (2012) 1.04
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer (2006) 1.04
Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies. Gynecol Oncol (2005) 1.03
Carcinosarcoma of the ovary-a case series. Gynecol Oncol (2005) 1.03
Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res (2011) 1.03
A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma. Gynecol Oncol (2011) 1.02
DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci (2008) 1.01
A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer (2010) 1.01
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol (2008) 1.01
A prospective evaluation of a simulator-based laparoscopic training program for gynecology residents. J Am Coll Surg (2007) 1.00
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res (2003) 0.99
Lower risk of cervical intraepithelial neoplasia in women with high plasma folate and sufficient vitamin B12 in the post-folic acid fortification era. Cancer Prev Res (Phila) (2009) 0.99
A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses. Gynecol Oncol (2005) 0.98